{rfName}
Pr

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Garcia-Carretero, RCorresponding AuthorTorres-Pacho, NAuthor
Share
Publications
>
Article

Predictive modeling of hypophosphatasia based on a case series of adult patients with persistent hypophosphatasemia

Publicated to:Osteoporosis International. 32 (9): 1815-1824 - 2021-09-01 32(9), DOI: 10.1007/s00198-021-05885-8

Authors: Garcia-Carretero, R; Olid-Velilla, M; Perez-Torrella, D; Torres-Pacho, N; Darnaude-Ortiz, M -T; Bustamate-Zuloeta, A -D; Tenorio, J -A

Affiliations

La Paz Univ Hosp, Inst Med & Mol Genet INGEMM, Madrid, Spain - Author
Mostoles Univ Hosp, Dept Clin Genet, Madrid, Spain - Author
Mostoles Univ Hosp, Dept Internal Med, Madrid, Spain - Author
Mostoles Univ Hosp, Dept Lab Clin Anal, Madrid, Spain - Author
Rey Juan Carlos Univ, Mostoles Univ Hosp, Dept Internal Med, Madrid, Spain - Author
See more

Abstract

Approximately half of individuals with hypophosphatasemia (low levels of serum alkaline phosphatase) have hypophosphatasia, a rare genetic disease in which patients may have stress fractures, bone and joint pain, or premature tooth loss. We developed a predictive model based on specific biomarkers of this disease to better diagnose this condition. Introduction Hypophosphatasemia is a condition in which low levels of alkaline phosphatase (ALP) are detected in the serum. Some individuals presenting with this condition may have a rare genetic disease called hypophosphatasia (HPP), which involves mineralization of the bone and teeth. Lack of awareness of HPP and its nonspecific symptoms make this genetic disease difficult to diagnose. We developed a predictive model based on biomarkers of HPP such as ALP and pyridoxal 5 '-phosphate (PLP), because clinical manifestations sometimes are not recognized as symptoms of HPP. Methods We assessed 325,000 ALP results between 2010 and 2015 to identify individuals suspected of having HPP. We performed univariate and multivariate analyses to characterize the relationship between hypophosphatasemia and HPP. Using several machine learning algorithms, we developed several models based on biomarkers and compared their performance to determine the best model. Results The final cohort included 45 patients who underwent a genetic test. Half (23 patients) showed a mutation of the ALPL gene that encodes the tissue-nonspecific ALP enzyme. ALP (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.3-0.8, p = 0.01) and PLP (OR 1.06, 95% CI 1.01-1.15, p = 0.04) were the only variables significantly associated with the presence of HPP. Support vector machines and logistic regression were the machine learning algorithms that provided the best predictive models in terms of classification (area under the curve 0.936 and 0.844, respectively). Conclusions Given the high probability of a misdiagnosis, its nonspecific symptoms, and a lack of awareness of serum ALP levels, it is difficult to make a clinical diagnosis of HPP. Predictive models based on biomarkers are necessary to achieve a proper diagnosis. Our proposed machine learning approaches achieved reasonable performance compared to traditional statistical methods used in biomedicine, increasing the likelihood of properly diagnosing such a rare disease as HPP.

Keywords
AdultAlkaline phosphataseAlplAlpl geneArticleBoneBone and bonesClinical articleCohortCohort analysisDiagnostic errorDiseaseDisease courseFemaleGeneGene mutationGenetic codeGenetic screeningGenetic testingGeneticsHumanHumansHypophosphatasemiaHypophosphatasiaHypophosphatemiaLogistic-regressionMachine learningMaleMathematical modelMutationPredictive modelPredictive valueProtein blood levelPyridoxal 5 phosphatePyridoxal phosphateRetrospective studySpectrumStatisticsSupport vector machine

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Osteoporosis International due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 2.69, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-06, the following number of citations:

  • WoS: 5
  • Scopus: 5
  • Europe PMC: 4
  • OpenCitations: 5
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-06:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 20 (PlumX).
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (García Carretero, Rafael) .

the author responsible for correspondence tasks has been García Carretero, Rafael.